Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Short Interest Update

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was the recipient of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 3,850,000 shares, a decrease of 8.3% from the December 15th total of 4,200,000 shares. Based on an average daily trading volume, of 606,000 shares, the short-interest ratio is currently 6.4 days. Approximately 6.7% of the company’s stock are sold short.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock traded down $1.44 during mid-day trading on Friday, hitting $121.18. 388,542 shares of the company traded hands, compared to its average volume of 538,909. The stock has a market cap of $7.33 billion, a price-to-earnings ratio of 17.07, a price-to-earnings-growth ratio of 0.88 and a beta of 0.56. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $134.17. The stock has a fifty day moving average price of $122.78 and a 200-day moving average price of $114.67. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Wall Street Analyst Weigh In

Several brokerages have recently commented on JAZZ. HC Wainwright reiterated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Royal Bank of Canada restated an “outperform” rating and set a $179.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Piper Sandler restated an “overweight” rating and set a $163.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $140.00 to $175.00 in a report on Thursday, December 12th. Finally, Robert W. Baird raised their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $177.00.

Insiders Place Their Bets

In other news, CEO Bruce C. Cozadd sold 2,000 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the sale, the chief executive officer now owns 427,025 shares in the company, valued at $51,742,619.25. This represents a 0.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 8,253 shares of company stock worth $1,001,434. Insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Itau Unibanco Holding S.A. purchased a new position in shares of Jazz Pharmaceuticals during the second quarter worth approximately $29,000. EverSource Wealth Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 97 shares in the last quarter. UMB Bank n.a. increased its stake in shares of Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after buying an additional 129 shares during the period. GAMMA Investing LLC increased its stake in shares of Jazz Pharmaceuticals by 41.3% in the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 121 shares during the period. Finally, Venturi Wealth Management LLC increased its stake in shares of Jazz Pharmaceuticals by 577.0% in the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after buying an additional 704 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.